GW PHARMA LIMITED
Company Information
- Company Number
- 03704998
- Registered Address
- Sovereign House Vision Park, Chivers Way, Histon, Cambridge, CB24 9BZ
- Status
- Active
- Employee Count
- 308
- Turnover
- £561,065,000
- EBITDA
- -£34,292,000
Additional Details
- Website
- https://gwpharm.com
- Company Type
- Private limited Company
- Incorporated On
- 29 January 1999
- Nature of Business
- 21200 - Manufacture of pharmaceutical preparations
- Industries
- Life Sciences And Medical Technology
- Region
- East of England
Time to Pay
Payment Timeline
Payment Features
Payment Score History
Performance Reports History
| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jan 2021 - 30 Jun 2021 | 27 Jul 2021 | 24 | 84% | 14% | 2% | 16% |
| 01 Jul 2020 - 31 Dec 2020 | 29 Jan 2021 | 23 | 87% | 12% | 1% | 17% |
Payment Time Trends
Payment Distribution Trends
Invoice Payment Practices
This information is as reported by the business, and responses are in their own words.
Payment Terms
Standard payment terms
Payment terms cover a variety of different payment terms, subject to the nature of the contract and the invoice. Typical payment terms can include: 7 Days 14 Days 30 Days 60 Days 20th day of the following month 30 Days from end of month
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
Intercompany invoices and performance have been excluded from reported statistics as these entirely relate to transactions between wholly owned group companies, and would distort performance if included.
Maximum contractual payment period agreed
60
Dispute Resolution Process
Invoices are matched by a dedicated Accounts Payable team on receipt, and disputed invoices are notified to the supplier. Any disputes are managed directly with the supplier and investigated to resolve them in a timely manner. Disputes may arise due to, but not limited to, the following circumstances: • Non-receipt of invoice • Non-receipt of goods • Delivered product/service does not agree to invoice • Incomplete or incorrect information • Incorrect address or company name • VAT requirements • Change of details (i.e. new bank account)
Other Payment Information
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
Company Summary
GW Pharma Limited is a UK-based biopharmaceutical company that specializes in developing and commercializing innovative cannabinoid-based medicines. Founded in 1998, the company is dedicated to improving the lives of patients with serious and life-threatening conditions through their products.
The company's sustainability program focuses on reducing their environmental impact by implementing sustainable practices in their operations and using renewable energy sources. They also prioritize ethical and responsible sourcing of their raw materials and strive to support local communities.
GW Pharma's main product is Sativex, an oral spray that has been approved in over 25 countries for the treatment of spasticity due to multiple sclerosis. They are also developing other cannabinoid-based medicines for various conditions such as epilepsy, autism, and glioblastoma.
The key people at GW Pharma include CEO Justin Gover, who has been with the company since 1999, and Dr. Geoffrey Guy, the founder and chairman of the board. The company has a team of experienced scientists, researchers, and executives who work together to bring their innovative medicines to patients.
For more information on GW Pharma and their products, you can visit their website at www.gwpharm.com. Their registered office address is Sovereign House, Vision Park, Histon, Cambridge, CB24 9BZ, United Kingdom.
